Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Details Narrative)

v3.8.0.1
Fair Value Measurements (Details Narrative) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2017
Jul. 07, 2017
Jun. 21, 2017
Dec. 31, 2016
Business combination, contingent consideration liabilities $ 250     $ 260
Prefunded Warrants [Member]        
Warrant to purchase shares of common stock   2,600,000 2,600,000  
Underwriter Warrants[Member]        
Warrant to purchase shares of common stock     575,000  
RedPath Integrated Pathology, Inc [Member] | Termination Agreement [Member]        
Business combination, contingent consideration liabilities 6,000      
Business combination, operating expenses $ 5,800